- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, including the execution of a clinical collaboration agreement with Merck to supply KEYTRUDA® (pembrolizumab ...

Exhibit 99.1 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T- cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, ...

As of the cutoff date, CX-904 demonstrated a favorable safety profile that supports administration and monitoring of enrolled patients in an outpatient setting. 1 There were no observed cases of cytokine release syndrome (CRS) of any grade in step-dosing cohorts as of the cutoff date. In non-step dosing cohorts, only Grade 1 CRS was observed in patients treated at the highest dose of 6 mg. Overall, the most common treatment-related adverse events (TRAEs) were rash, arthralgia, arthritis, pruritis, and vomit ...

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -                   - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma - SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- CytomX Ther ...

CytomX Therapeutics (CTMX) shares soared 214.7% in the last trading session to close at $5.13. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 23.8% loss over the past four weeks.Last month, the company announced the dosing of the first patient in a phase I dose-escalation study evaluating its pipeline candidate, CX-2051, in patients with advanced solid tumors. This might have driven the share price rally.This biopharmaceutical c ...

CytomX (NASDAQ:CTMX) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report.The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024. It will also host a conference call that same day starting at 5:00 p.m. Eastern Time.Investors will want to keep an eye on EPS and revenue as two important metrics in this earnings report. Wall Street ...

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer typ ...

- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies' TCB collaboration with Astellas, triggering a $5 million milestone payment ...

- Initiation of GLP toxicology study for the first clinical candidate in the collaboration triggers a $5 million milestone payment to CytomX - - Program is one of several ongoing collaboration projects in broad CytomX-Astellas alliance on T-cell engaging bispecifics - - CytomX retains option for US co-commercialization and economic rights for certain programs - SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally acti ...

CytomX Therapeutics (NASDAQ:CTMX) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report.The CytomX Therapeutics earnings report notes that the company spent most of 2023 cutting costs to continue operations. That saw its 2023 operating expenses come in at $107.7 million as compared to $154.5 million in 2022.CytomX Therapeutics notes that a large portion of these savings came from a workforce reduction in 2022. That resulted ...